References - Therapeutic Strategies in Cancer Biology and Pathology - page 257

Wei, H.J., Yin, T., Zhu, Z., Shi, P.F., Tian, Y., Wang, C., 2011. Expression of CD44, CD24
and ESA in pancreatic adenocarcinoma cell lines varies with local microenvironment.
Hepatobiliary Pancreatic Dis. Int. 10, 428-434.
Wei, N., Liu, S.S., Chan, K.K.L., Ngan, H.Y.S., 2012a. Tumour suppressive function and mod-
ulation of programmed cell death 4 (PDCD4) in ovarian cancer. Plos ONE 7, e30311.
Wei, Q.J., He, W., Lu, Y.J., Yao, J., Cao, X., 2012b. Effect of the tumor suppressor gene ING4
on the proliferation of MCF-7 human breast cancer cells. Oncol. Lett. 4, 438-442.
Weir, B.A., Woo, M.S., Getz, G., Perner, S., Ding, L., Beroukhim, R., et al., 2007.
Characterizing the cancer genome in lung adenocarcinoma. Nature 450, 893-898.
Welsh, S., Williams, R., Kirkpatrick, L., Paine-Murrieta, G., Powis, G., 2004. Antitumor activ-
ity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-
1alpha. Mol. Cancer Ther. 3, 233-244.
Wen, Y., Wang, Q., Zhou, C., Yan, D., Qiu, G., Yang, C., et al., 2011. Decreased expression of
RASSF6 is a novel independent prognostic marker of a worse outcome in gastric cancer
patients after curative surgery. Ann. Surg. Oncol. 18, 3858-3867.
Wen, Y.H., Shi, X., Chiriboga, L., Matsahash, S., Yee, H., Afonja, O., 2007. Alterations in the
expression of PDCD4 in ductal carcinoma of the breast. Oncol. Res. 18, 1387-1393.
Wen, Y.H., Ho, A., Patil, S., Akram, M., Catalano, J., Eaton, A., et al., 2012. Id4 protein is
highly expressed in triple negative breast carcimnomas: possible implications for BRCA1
downregulation. Breast Cancer Res. Treat. 135, 93-102.
West, A., Vojta, P.J., Welch, D.R., Weissman, B.E., 1998. Chromosome localization and genomic
structure of the KiSS-1 metastasis suppressor gene (KISS1). Genomics 54, 145-148.
Will, M.A., Palaniappan, M., Peegel, H., Kayampilly, P., K.M.J., Menon, 2012. Metformin:
direct inhibition of rat ovarian theca-interstitial cell proliferation. Fertility Sterility 98,
207-214.
Williams, J.A., Guicherit, O.M., Zaharian, B.I., Xu, Y., Chai, L., Wichterle, H., et al., 2003.
Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on
basal cell carcinoma-like lesions. Proc. Natl. Acad. Sci. U.S.A. 100, 4616-4621.
Williams, J.A., Thomas, A.M., Li, G., Kong, B., Zhan, L., Inaba, Y., et al., 2012. Tissue spe-
cific induction of p62/Sqstm1 by farnesoid X receptor. PloS ONE 7, e43961.
Williams, S.A., Maecker, H.L., French, D.M., Liu, J., Gregg, A., Silverstein, L.B., et al. 2011.
USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteo-
sarcoma. Cell 146, 917-929.
Wingo, S.N., Gallardo, T.D., Akbay, E.A., Liang, M.C., Contreras, C.M., Boren, T., et al., 2009.
Somatic LKB1 mutations promote cervical cancer progression. PLoS ONE 4, e5137.
Winter, J., Jung, S., Keller, S., Gregory, R.I., Sven Diederichs, S., 2009. Many roads to matu-
rity: microRNA biogenesis pathways and their regulation. Nat. Cell Biol. 11, 228-234.
Wong, C.M., Yam, J.W., Ching, Y.P., et al., 2005. Rho GTPase-activating protein deleted in
liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.
Cancer Res. 65, 8861-8868.
Wong, H., Chen, J.Z., Chou, B., Halladay, J.S., Kenny, J.R., La, H., et al., 2009. Preclinical
assessment of the absorption, distribution, metabolism and excretion of GDC-0449
(2-chloro- N -(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally
bioavailable systemic Hedgehog signalling pathway inhibitor. Xenobiotica 39, 850-861.
Wong, I.H.N., Chan, J., Wong, J., Tam, P.K.H., 2004. Ubiquitous aberrant RASSF1A pro-
moter methylation in childhood neoplasia. Clin. Cancer Res. 10, 994-1002.
Wong, K.Y., So, C.C., Loong, F., Chung, L.P., Lam, W.W.L., Liang, R., et al., 2011.
Epigenetic inactivation of the miR-124-1 in haematological malignancies. Plos ONE 6,
e19027.